xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

352

KUANetal.

TABLE XXXII.1 (Continued)

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

Tyler et al. 2113

1. On the MDASI, xerostomia was the most burdensome symptom, followed by problems tasting food and difficulty swallowing/chewing 2. On the ASBQ, poor smell had the highest burden, followed by nasal secretions, poor sense of taste, and lack of energy 3. Advanced T3/T4 tumors were associated with worse ASBQ total scores 1. QOL in patients with malignant tumors decreased from preoperatively to 6 months postoperatively, but increased back to baseline by 12 months postoperatively 2. For patients with malignant tumors, decreases in QOL at 6 months and subsequent increases at 12 months were seen in the role emotional, specific symptoms, pain, vitality, and physical function domains 1. Based on the ALHR, most patients were very satisfied with their lives 2. Based on the CES-D, there were higher rates of depression in this cohort 3. On the MDS, 69% and 61% reported disturbance of smell and nasal crusting, respectively 4. Postop RT was associated with reduced FACT-HN subscale scores 1. Patients with ASB malignancy scored lower than those with lateral skull base malignancy on UW-QOL scale 2. For those with ASB tumors, taste, mood, anxiety, activity, and recreation were the worst individual domains 3. Three and four patients had probable anxiety and depression, respectively (Continues)

QOL as measured by the EQ-5D VAS, MDASI, andASBQ

2020 3

Cross-sectional study

114 patients with sinonasal or

nasopharyngeal malignancy treated with surgery, RT, and/or chemotherapy

Abergel et al. 2114 2010 3

Prospective cohort

17 patients with

1. QOLas

malignant skull base tumors undergoing open anterior skull base surgery with or withoutRT

measured by theASBQat 6months measured by theASBQat 12months

2. QOLas

Palme et al. 2120

QOL as measured by the FACT-HN, CES-D, ALHR, andMDSat a median follow-up of 5 years

2009 3

Cross-sectional study

27 patients with skull base tumors (20 malignancy) undergoing surgery with postoperative

RT( n = 16) and chemotherapy ( n = 2)

Martinez Devesa et al. 2121

2006 3

Cross-sectional study

18 patients treated for skull base malignancy with surgery and/or RT

QOL as measured by the UW-QOL andHADS